174 related articles for article (PubMed ID: 10410147)
1. [Docetaxel therapy against anthracycline resistant breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y; Suzuma T; Tanino H
Gan To Kagaku Ryoho; 1999 May; 26(6):781-8. PubMed ID: 10410147
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
7. [Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].
Nagai S; Toi M; Kuroi K; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2037-42. PubMed ID: 10584568
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
Ikeda H; Koshiba R
Gan To Kagaku Ryoho; 2001 May; 28(5):637-41. PubMed ID: 11383211
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
10. [Two cases of recurrent breast cancer successfully treated with paclitaxel weekly therapy].
Tagaya N; Nakagawa A; Okada T; Hamada K; Mikami H; Ito S; Kubota K
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1479-83. PubMed ID: 14584281
[TBL] [Abstract][Full Text] [Related]
11. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
12. [Breast cancer with liver metastasis responsive to docetaxel: case report].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):743-6. PubMed ID: 9571974
[TBL] [Abstract][Full Text] [Related]
13. The role of taxanes in the treatment of breast cancer.
Capri G; Tarenzi E; Fulfaro F; Gianni L
Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
[TBL] [Abstract][Full Text] [Related]
14. [A case of docetaxel-resistant breast cancer responsive to paclitaxel therapy].
Oura S; Tanino H; Yoshimasu T; Sakurai T; Nakamura T; Kokawa Y; Matsuyama K; Naito Y
Gan To Kagaku Ryoho; 2001 Apr; 28(4):511-4. PubMed ID: 11329786
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study.
Ferraresi V; Milella M; Vaccaro A; D'Ottavio AM; Papaldo P; Nisticò C; Thorel MF; Marsella A; Carpino A; Giannarelli D; Terzoli E; Cognetti F
Am J Clin Oncol; 2000 Apr; 23(2):132-9. PubMed ID: 10776972
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Hellenic Cooperative Interhospital Group in Oncology.
Alexopoulos CG; Rigatos G; Efremidis AP; Papacharalambous A; Alexopoulos A; Vassilomanolakis M; Patila E
Cancer Chemother Pharmacol; 1999; 44(3):253-8. PubMed ID: 10453728
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial.
Schmidinger M; Budinsky AC; Wenzel C; Locker GJ; Pluschnig U; Brodowicz T; Kubista E; Maca S; Zabernigg A; Ilsinger P; Seewann L; Hojas S; Blach M; Zielinski CC; Steger GG
Cancer Chemother Pharmacol; 2001; 47(1):57-62. PubMed ID: 11221963
[TBL] [Abstract][Full Text] [Related]
19. Monotherapy with paclitaxel as third-line chemotherapy against anthracycline-pretreated and docetaxel-refractory metastatic breast cancer.
Kinoshita J; Haga S; Shimizu T; Imamura H; Watanabe O; Nagumo H; Utada Y; Okabe T; Kimura K; Hirano A; Kajiwara T
Breast Cancer; 2002; 9(2):166-9. PubMed ID: 12016397
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
